Home » AIFA approves the reimbursement of a new drug for thyroid cancer – Focus Tumor news

AIFA approves the reimbursement of a new drug for thyroid cancer – Focus Tumor news

by admin
AIFA approves the reimbursement of a new drug for thyroid cancer – Focus Tumor news

A new therapeutic option for thyroid cancer: the Italian Medicines Agency (Aifa) has approved reimbursement for cabozantinib tablets for the treatment of differentiated thyroid cancer refractory to radioactive iodine therapy.

“The approval of the reimbursement of cabozantinib for the treatment of differentiated thyroid carcinoma refractory to radioactive iodine therapy and progressing during first-line systemic medical therapy is an important result for the clinical management of these patients”, said Rossella Elisei, president of the Italian Thyroid Association. “The real meaning is to have another therapeutic weapon available for these patients who will thus be able to gain additional months and years of life.”

In particular, explains Laura Locati, director of the complex structure of Oncology at the Maugeri Irccs Scientific Clinical Institutes of Pavia, “the effectiveness of cabozantinib was tested in a randomized study, where cabozantinib was shown to reduce the probability of progression of thyroid cancer in the 78% compared to the placebo, thus responding to a specific need for which, to date, there was still no standard of care. In the Cosmic-311 study the median progression-free survival was 11 months”.

AIFA’s approval follows the positive opinion of the European Medicines Agency which expressed itself in March 2022. In consideration of the important unmet clinical need and the added therapeutic value, the drug had in any case already been made available free of charge to Italian patients starting from October 2021, in accordance with law 648/1996 which regulates the early use of innovative drugs not yet available in Italy.

breaking latest news © Copyright ANSA

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy